Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	48
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	37
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	31
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	31
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	26
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	26
Organ toxicities associated with chimeric antigen receptor T-cell therapy	25
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	23
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	23
Hypereosinophilia after CAR T-cell therapy	23
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	21
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	20
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	20
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	20
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	19
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	19
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	18
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	18
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	17
T-cell/histiocyte-rich large B-cell lymphoma, insights into prognosis and treatment complexity in the context of immunotherapeutics	17
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	16
Management of relapsed/refractory mantle cell lymphoma	16
XX International workshop on chronic lymphocytic leukemia	16
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	16
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	15

Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	15
Significant variations in first-line mantle cell lymphoma care—an Australasian Lymphoma and Related Diseases Registry study	15
The maturing picture of CPX-351 in acute myeloid leukemia: long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in England	14
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	14
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy	14
Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance	14
Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma	14
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	14
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	14
ELN 2025 and somatic NGS in CML: a pragmatic framework for selective testing and interpretation beyond BCR::ABL1	14
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	13
Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine	13
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	13
Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia	13
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	13
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	13
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	13
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study	13
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	13
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	13
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	12
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	12
Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review	12
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	12
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia	12
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	12
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	12
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	12
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	12
Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CML	11
Donor-derived somatic genetic rescue with prolonged hematopoietic stability following sibling allogeneic stem cell transplant in SAMD9 syndrome	11
Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study	11
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	11
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	11
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	11
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	11
Homocysteine-driven oxidative stress in pediatric lymphoma: a cross-sectional study of metabolic and genetic modulators	11
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	11
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	10
Clonal ancestry in AML: insights from founding genetic events	10
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	10
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	10
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	10
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	10
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	10
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	10
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	10
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	9
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	9

The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Factors associated with long-term quality of life after allogenic stem cell transplantation	9
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	9
Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes	9
Correction	9
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	9
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	9
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	9
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred	9
Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients	9
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	9
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	9
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	8
Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors	8
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	8
Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis	8
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	8
Emerging drug profile: JAK inhibitors	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	8
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	8
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	8
Prospects for liquid biopsy approaches in lymphomas	8
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	8
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	8
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	8
Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma	8
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	8
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron da	8
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	8
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	8
Clinicopathologic features of lymphoma-associated hemophagocytic lymphohistiocytosis in a multicenter adult cohort	7
Efficacy of CD19 CAR T-cell therapy in active vitreoretinal lymphoma	7
Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	7
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	7
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	7
Sepsis and mucositis-related biomarkers in adult hematologic patients with febrile neutropenia	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7
Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant	7
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives	7
Mitigating time toxicity in lymphoma and multiple myeloma	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1 -positive AML: results from AML-CAMS seria	7
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	7
Recipient polymorphism of the C-reactive protein (CRP) gene rs2794521 stratified disease-free survival, but did not influence maximum serum CRP levels during neutropenia after single-unit cord blood t	7
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma	7
CALR -mutated myeloproliferative neoplasms	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	7
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence	7
Risk prediction model and survival analysis of adult patients with intracranial hemorrhage in acute leukemia	7
Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	6
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	6
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	6
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	6
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data	6
Intentional CYP3A4 inhibition in venetoclax-based AML therapy: from incidental observation to validated clinical strategy	6
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	6

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Leukocytosis and MPNs: Where do we stand?	6
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation	6
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	6
Bridging therapeutic gaps in B‑ALL: a peri‑transplant Inotuzumab approach	6
Response-adapted de-escalation of radiotherapy in pediatric Hodgkin’s lymphoma	6
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744)	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
XXI International Workshop on CLL 2025	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Lineage switch from B-ALL to AML via an intervening MDS/MPN phase with acquisition of RBM15::MKL1 and RAD21	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	6
Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia	5
A retrospective analysis of factors impacting survival in United States military veterans with multiple myeloma	5
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	5
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	5
Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study	5
Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review	5
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	5
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	5
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Diffuse large B-cell lymphoma outcomes in an urban safety-net cohort: functional status, clinical risk, and treatment feasibility	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort	5
Correction	5
Follicular lymphoma: an update on biology and optimal therapy	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to speci	5
Epcoritamab for diffuse large B-cell lymphoma in a dialysis-dependent patient	5
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	5
Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis	5
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	5
Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications	5
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	5
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia	5
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring	5
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	5
Correction	5
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report	5
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation	5
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old	5
Temporal improvements in survival with persistent disparities in acute myeloid leukemia: a two-decade population-based analysis from the United States	5
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	5
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity	5
Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis	5
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis	5
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	5
Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape	5
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	5
Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL)	5
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study	5
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16	5
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	5
Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National	4
Correction	4
The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma	4
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study	4
Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation	4
Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin	4
SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era	4
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy	4
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma	4
Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience	4
Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation	4
Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity	4
HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML	4
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series	4
Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?	4
Infections during novel myeloma therapies	4
Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis	4
Thrombosis in multiple myeloma: mechanisms, risk assessment and management	4
Neuroendocrine transdifferentiation of aggressive B-cell leukemia/lymphoma post CAR-T therapy	4
Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN)	4
Effective management of daratumumab-induced cytopenias with hematopoietic stem cell infusion in relapsed/refractory multiple myeloma: a case report	4
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure	4
Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study	4
Routine follow-up practices in patients with lymphoma: a nationwide survey by the Italian lymphoma foundation	4
Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL	4
Diagnosis and management of acute erythroid leukemia (AEL)	4